Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Anbio BiotechnologyNNNN -1.24%24 EV-to-EBITDA is 61.49 as of Aug. 19, 2026, which is 68% below its 10-year median of 193.66. GuruFocus rates NNNN with a GF Score™ of 24/100. The stock has 2 warning signs investors should review. Among 513 Medical Devices & Instruments companies, Anbio Biotechnology ranks worse than 91.42% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Anbio Biotechnology's enterprise value is $354.58 Mil.
Anbio Biotechnology's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was $5.77 Mil. Therefore, Anbio Biotechnology's EV-to-EBITDA for today is 61.49.
The historical rank and industry rank for Anbio Biotechnology's EV-to-EBITDA or its related term are showing as below:
NNNN'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 58.29 Med: 193.66 Max: 1117.45
Current: 61.49
During the past 5 years, the highest EV-to-EBITDA of Anbio Biotechnology was 1117.45. The lowest was 58.29. And the median was 193.66.
NNNN's EV-to-EBITDA is ranked worse than 91.42% of 513
companies
in the Medical Devices & Instruments industry
Industry Median: 14.77
vs NNNN: 61.49
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Anbio Biotechnology's PE Ratio (TTM) for today is calculated as:
Anbio Biotechnology's share price for today is $8.40.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Anbio Biotechnology's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was $0.147.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Anbio Biotechnology's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Anbio Biotechnology's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Anbio Biotechnology EV-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Anbio Biotechnology's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Anbio Biotechnology's EV-to-EBITDA falls into.
Anbio Biotechnology's current Enterprise Value is $354.58 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Anbio Biotechnology's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was $5.77 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Anbio Biotechnology (NNNN) has a EV-to-EBITDA of 61.49 as of Aug. 19, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Anbio Biotechnology. This is 68% below median its historical median of 193.66. Over the past decade, Anbio Biotechnology's EV-to-EBITDA has ranged from 58.29 to 1,117.45. According to the industry distribution chart, Anbio Biotechnology ranks #469 out of 513 companies in the Medical Devices & Instruments industry, placing it in the top 91.4%.
Is Anbio Biotechnology's EV-to-EBITDA too high?
Anbio Biotechnology's current EV-to-EBITDA of 61.49 is 68% below median its 10-year median of 193.66. Over the past 10 years, this metric has ranged from a low of 58.29 to a high of 1,117.45. The Medical Devices & Instruments industry median EV-to-EBITDA is 14.77. Anbio Biotechnology's value of 61.49 is 316.3% above this industry median. Based on the distribution chart, Anbio Biotechnology ranks #469 out of 513 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Anbio Biotechnology has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does Anbio Biotechnology's EV-to-EBITDA compare to ANGO and OSUR?
According to the Medical Devices & Instruments industry distribution chart, Anbio Biotechnology ranks #469 out of 513 companies for EV-to-EBITDA. This places Anbio Biotechnology in the lower half of its industry. The industry median EV-to-EBITDA is 14.77. Anbio Biotechnology's value of 61.49 is 316.3% above this benchmark. Historically, Anbio Biotechnology's own EV-to-EBITDA has ranged from 58.29 to 1,117.45 over the past decade. While the company's 10-year median is 193.66 vs. the industry median of 14.77, Anbio Biotechnology has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Devices & Instruments company?
The median EV-to-EBITDA among Medical Devices & Instruments companies is 14.77, based on 513 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Anbio Biotechnology's current EV-to-EBITDA of 61.49 is 316.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Anbio Biotechnology. For the Medical Devices & Instruments industry, the median EV-to-EBITDA is 14.77 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Anbio Biotechnology's current EV-to-EBITDA is 61.49, which is 68% below median its own 10-year median of 193.66. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anbio Biotechnology stock overvalued right now?
Anbio Biotechnology (NNNN) has a current EV-to-EBITDA of 61.49. The current EV-to-EBITDA is 61.49, which is 68% below median its 10-year median of 193.66 and 316.3% above the Medical Devices & Instruments industry median of 14.77. Anbio Biotechnology's overall GF Score™ is 24/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Anbio Biotechnology (NNNN), the current EV-to-EBITDA is 61.49 as of Aug. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Anbio Biotechnology is a medical device company focused on in vitro diagnostics. The company's mission is to change the diagnostics market by personalizing and decentralizing the current diagnostic solutions for faster diagnosis to improve patient prognosis. The company proposes this by providing accessible and affordable diagnostic solutions globally at the forefront of science and offering laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions. The business planning is to focus on validating and commercializing the existing portfolio of in vitro diagnostic products, as well as generating additional data required to support regulatory submissions and compliance, including under frameworks such as the In Vitro Diagnostic Regulation (IVDR).
24GF Score
Get the complete analysis for NNNN
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NNNN has been successfully added to your 
